Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
NCT01572480Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2012
- Primary completion
- Mar 2022
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in smoldering multiple myeloma (SMM), sponsored by National Cancer Institute. Started May 2012; status: completed.
02
Drugs
carfilzomib
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT01572480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01572480.